Journal of Infection最新文献

英文中文

Corrigendum to “No evidence of difference in mortality with amoxicillin versus co-amoxiclav for hospital treatment of community-acquired pneumonia” [J Infect 88 (2024) 106161]

IF 14.3 1区医学 Q1 INFECTIOUS DISEASES

Journal of Infection

Pub Date : 2024-12-01 DOI: 10.1016/j.jinf.2024.106361

Jia Wei , Aashna Uppal , Christy Nganjimi , Hermione Warr , Yasin Ibrahim , Qingze Gu , Hang Yuan , Najib M. Rahman , Nicola Jones , A.Sarah Walker , David W. Eyre

引用次数: 0

Impact of Respiratory Syncytial Virus (RSV) on adult haematology oncology patients 呼吸道合胞病毒 (RSV) 对成人血液肿瘤科患者的影响。

IF 14.3 1区医学 Q1 INFECTIOUS DISEASES

Journal of Infection

Pub Date : 2024-12-01 DOI: 10.1016/j.jinf.2024.106347

F. Farina, D. Sannipoli, E. Diral, S. Mastaglio, C. Oltolini, R. Dell’Acqua, M. Marcatti, V. Ferla, L. Canziani, E. Xue, D. Clerici, A. Bruno, S. Marktel, MG Carrabba, M. Bernardi, A. Carmagnola, V. Spagnuolo, P. Scarpellini, M. Moro, J. Peccatori, MT Lupo-Stanghellini

引用次数: 0

Contaminated bacterial genome data in the public domains: Evidence and solution.

IF 14.3 1区医学 Q1 INFECTIOUS DISEASES

Journal of Infection

Pub Date : 2024-12-01 Epub Date: 2024-11-26 DOI: 10.1016/j.jinf.2024.106369

Biao Tang, Xiaohe Hu, Min Yue

引用次数: 0

Real-world effectiveness and safety of azvudine in hospitalized patients with SARS-CoV-2 infection: A multicenter, retrospective cohort study 阿兹夫定对感染 SARS-CoV-2 的住院病人的实际有效性和安全性：一项多中心、回顾性队列研究。

IF 14.3 1区医学 Q1 INFECTIOUS DISEASES

Journal of Infection

Pub Date : 2024-12-01 DOI: 10.1016/j.jinf.2024.106355

Zhigang Ren , Mengzhao Yang , Guanyue Su , Guowu Qian , Yiqiang Yuan , Jia Yu , Silin Li , Changshuang Wang , Mingxia Lu , Hong Luo , Shixi Zhang , Guangming Li , Donghua Zhang , Ling Wang , Guotao Li , Xiaoli Jin , Juan Wang , Mingming Wang , Ming Cheng , Haiyu Wang , Zujiang Yu

Objectives

Azvudine has been designated as a priority treatment for patients infected with SARS-CoV-2, however, clinical evidence in hospitalized cases remains insufficient.

Methods

We performed a multi-center, retrospective cohort study to evaluate the effectiveness and safety of azvudine in hospitalized patients with SARS-CoV-2 in China (NCT06349655). Kaplan-Meier method, Cox regression model, subgroup analysis, and seven sensitive analyses were employed.

Results

A total of 32864 hospitalized patients with SARS-CoV-2 were enrolled, in which 5735 azvudine recipients and 5735 controls were selected using 1:1 propensity score matching. Based on Kaplan-Meier analysis, azvudine significantly reduced rates of all-cause death (P < 0.0001) and composite disease progression (P = 0.00019). Cox regression analysis demonstrated that hazard ratios of all-cause death and composite disease progression were 0.68 (95%CI: 0.598–0.775, P < 0.001) and 0.88 (95% CI: 0.795–0.976, P = 0.016), respectively. Subgroup analysis showed preference of azvudine for patients receiving antibiotics in reducing all-cause death and composite disease progression. Seven sensitivity analyses verified the robustness of our results. Safety analysis on adverse events showed no significant difference between both groups.

Conclusions

This study suggested that azvudine may reduce all-cause death and composite disease progression in hospitalized patients with SARS-CoV-2 infection without serious adverse events. However, the findings are susceptible to some potential biases, and further studies still need to identify the efficacy of azvudine.

目的阿兹夫定已被指定为SARS-CoV-2感染者的优先治疗药物，但住院病例的临床证据仍然不足：我们进行了一项多中心、回顾性队列研究，评估阿兹夫定在中国 SARS-CoV-2 住院患者中的有效性和安全性（NCT06349655）。研究采用了卡普兰-梅耶法、考克斯回归模型、亚组分析和七项敏感性分析：共纳入 32864 名 SARS-CoV-2 住院患者，其中 5735 名阿兹夫定接受者和 5735 名对照者采用 1:1 倾向评分匹配法进行匹配。根据 Kaplan-Meier 分析，阿兹夫定可显著降低全因死亡率（P < 0.0001）和复合疾病进展率（P = 0.00019）。Cox 回归分析显示，全因死亡和复合疾病进展的危险比分别为 0.68（95%CI：0.598-0.775，P < 0.001）和 0.88（95%CI：0.795-0.976，P = 0.016）。亚组分析显示，接受抗生素治疗的患者更倾向于使用阿兹夫定，以减少全因死亡和复合疾病进展。七项敏感性分析验证了我们结果的稳健性。对不良事件的安全性分析表明，两组之间没有明显差异：这项研究表明，阿兹夫定可减少 SARS-CoV-2 感染住院患者的全因死亡和综合疾病进展，且不会出现严重不良反应。结论：这项研究表明，阿兹夫定可减少 SARS-CoV-2 感染住院患者的全因死亡和综合疾病进展，且无严重不良反应，但研究结果容易受到一些潜在偏差的影响，仍需进一步研究以确定阿兹夫定的疗效。

{"title":"Real-world effectiveness and safety of azvudine in hospitalized patients with SARS-CoV-2 infection: A multicenter, retrospective cohort study","authors":"Zhigang Ren , Mengzhao Yang , Guanyue Su , Guowu Qian , Yiqiang Yuan , Jia Yu , Silin Li , Changshuang Wang , Mingxia Lu , Hong Luo , Shixi Zhang , Guangming Li , Donghua Zhang , Ling Wang , Guotao Li , Xiaoli Jin , Juan Wang , Mingming Wang , Ming Cheng , Haiyu Wang , Zujiang Yu","doi":"10.1016/j.jinf.2024.106355","DOIUrl":"10.1016/j.jinf.2024.106355","url":null,"abstract":"<div><h3>Objectives</h3><div>Azvudine has been designated as a priority treatment for patients infected with SARS-CoV-2, however, clinical evidence in hospitalized cases remains insufficient.</div></div><div><h3>Methods</h3><div>We performed a multi-center, retrospective cohort study to evaluate the effectiveness and safety of azvudine in hospitalized patients with SARS-CoV-2 in China (NCT06349655). Kaplan-Meier method, Cox regression model, subgroup analysis, and seven sensitive analyses were employed.</div></div><div><h3>Results</h3><div>A total of 32864 hospitalized patients with SARS-CoV-2 were enrolled, in which 5735 azvudine recipients and 5735 controls were selected using 1:1 propensity score matching. Based on Kaplan-Meier analysis, azvudine significantly reduced rates of all-cause death (<em>P</em> < 0.0001) and composite disease progression (<em>P</em> = 0.00019). Cox regression analysis demonstrated that hazard ratios of all-cause death and composite disease progression were 0.68 (95%CI: 0.598–0.775, <em>P</em> < 0.001) and 0.88 (95% CI: 0.795–0.976, <em>P</em> = 0.016), respectively. Subgroup analysis showed preference of azvudine for patients receiving antibiotics in reducing all-cause death and composite disease progression. Seven sensitivity analyses verified the robustness of our results. Safety analysis on adverse events showed no significant difference between both groups.</div></div><div><h3>Conclusions</h3><div>This study suggested that azvudine may reduce all-cause death and composite disease progression in hospitalized patients with SARS-CoV-2 infection without serious adverse events. However, the findings are susceptible to some potential biases, and further studies still need to identify the efficacy of azvudine.</div></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"89 6","pages":"Article 106355"},"PeriodicalIF":14.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142677651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old COVID-19 接种和加强接种平台试验（PICOBOO）：对 18-<50 岁和 50-<70 岁的 BNT162b2 接种者进行 COVID-19 疫苗接种作为第二次加强接种的免疫原性、反应原性和安全性试验。

IF 14.3 1区医学 Q1 INFECTIOUS DISEASES

Journal of Infection

Pub Date : 2024-12-01 DOI: 10.1016/j.jinf.2024.106346

C. McLeod , M. Dymock , KL Flanagan , M. Plebanski , HS Marshall , MJ Estcourt , U. Wadia , MC Tjiam , CC Blyth , K. Subbarao , FL Mordant , S. Nicholson , N. Cain , R. Brizuela , SN Faust , RB Thornton , Z. Ellis , A. Mckenzie , JA Marsh , TL Snelling , PC Richmond

Objectives

PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.

Methods

Immunocompetent adults who had received two doses of BNT162b2 and any licensed COVID-19 booster at least three months prior were eligible. Participants were randomly allocated to BNT162b2, mRNA-1273 or NVX-CoV2373 1:1:1. The log₁₀ concentration of anti-spike Ig Total was summarised as the geometric mean concentration (GMC). Reactogenicity and safety outcomes were captured.

Results

Between Mar 2022 and Aug 2023, 743 participants were recruited to the trial and had D28 samples available. Of these, 120 and 103 belonged to the 18-<50 y and 50-<70 y strata, respectively. The mean adjusted GMCs (95% credible intervals) peaked at D28; these were 41 262 (31 611, 51 105), 45 585 (34 194, 57 441) and 25 281 (20 021, 31 234) U/mL in the 18-<50 y stratum and 30 753 (25 071, 36 704), 35 132 (27 523, 42 239) and 17 322 (13 983, 20 641) U/mL in the 50-<70 y stratum following BNT162b2, mRNA-1273 and NVX-CoV2373, respectively. Limited neutralisation against Omicron subvariants was found following boosting with all vaccines. There were 4 possibly or probably-related adverse events in the 18-<50 y stratum and 5 events in the 50-<70 y stratum, and severe reactogenicity events were <10% and <11% in these strata, respectively.

Conclusions

Vaccines targeting Ancestral virus elicited boosted antibody responses to Ancestral virus but minimal neutralising antibody against Omicron variants.

试验目的PICOBOO 是一项随机适应性试验，旨在评估 COVID-19 强化策略的免疫原性、反应原性和安全性。在此，我们收集了 18 岁以下人群第二次加强免疫的数据：至少在三个月前接受过两剂 BNT162b2 和任何获得许可的 COVID-19 强化剂的免疫功能正常的成年人均符合条件。参与者按 1:1:1 的比例随机分配到 BNT162b2、mRNA-1273 或 NVX-CoV2373。抗尖峰抗体 Ig 总浓度的 log10 值汇总为几何平均浓度 (GMC)。研究还采集了反应生成性和安全性结果：2022 年 3 月至 2023 年 8 月期间，743 名试验参与者获得了 D28 样本。其中120人和103人属于18-结论：针对祖先病毒的疫苗可增强对祖先病毒的抗体反应，但对奥米克隆变体的中和抗体反应却微乎其微。

{"title":"The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old","authors":"C. McLeod , M. Dymock , KL Flanagan , M. Plebanski , HS Marshall , MJ Estcourt , U. Wadia , MC Tjiam , CC Blyth , K. Subbarao , FL Mordant , S. Nicholson , N. Cain , R. Brizuela , SN Faust , RB Thornton , Z. Ellis , A. Mckenzie , JA Marsh , TL Snelling , PC Richmond","doi":"10.1016/j.jinf.2024.106346","DOIUrl":"10.1016/j.jinf.2024.106346","url":null,"abstract":"<div><h3>Objectives</h3><div>PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.</div></div><div><h3>Methods</h3><div>Immunocompetent adults who had received two doses of BNT162b2 and any licensed COVID-19 booster at least three months prior were eligible. Participants were randomly allocated to BNT162b2, mRNA-1273 or NVX-CoV2373 1:1:1. The log<sub>10</sub> concentration of anti-spike Ig Total was summarised as the geometric mean concentration (GMC). Reactogenicity and safety outcomes were captured.</div></div><div><h3>Results</h3><div>Between Mar 2022 and Aug 2023, 743 participants were recruited to the trial and had D28 samples available. Of these, 120 and 103 belonged to the 18-<50 y and 50-<70 y strata, respectively. The mean adjusted GMCs (95% credible intervals) peaked at D28; these were 41 262 (31 611, 51 105), 45 585 (34 194, 57 441) and 25 281 (20 021, 31 234) U/mL in the 18-<50 y stratum and 30 753 (25 071, 36 704), 35 132 (27 523, 42 239) and 17 322 (13 983, 20 641) U/mL in the 50-<70 y stratum following BNT162b2, mRNA-1273 and NVX-CoV2373, respectively. Limited neutralisation against Omicron subvariants was found following boosting with all vaccines. There were 4 possibly or probably-related adverse events in the 18-<50 y stratum and 5 events in the 50-<70 y stratum, and severe reactogenicity events were <10% and <11% in these strata, respectively.</div></div><div><h3>Conclusions</h3><div>Vaccines targeting Ancestral virus elicited boosted antibody responses to Ancestral virus but minimal neutralising antibody against Omicron variants.</div></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"89 6","pages":"Article 106346"},"PeriodicalIF":14.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Monocyte transcriptome signatures of inflammation and enhanced neutrophil recruitment characterize immunopathology in the blood of tuberculosis patients 结核病患者血液中的单核细胞炎症转录组特征和中性粒细胞招募增强是免疫病理的特征。

IF 14.3 1区医学 Q1 INFECTIOUS DISEASES

Journal of Infection

Pub Date : 2024-12-01 DOI: 10.1016/j.jinf.2024.106359

Hubert Senanu Ahor , Monika M. Vivekanandan , Ernest Adankwah , Difery Minadzi , Isaac Acheampong , Wilfred Aniagyei , Augustine Yeboah , Joseph F. Arthur , Millicent Lamptey , Mohammed K. Abass , Francis Kumbel , Francis Osei-Yeboah , Amidu Gawusu , Patrick Petzsch , Karl Köhrer , Linda Batsa Debrah , Dorcas O. Owusu , Alexander Debrah , Ertan Mayatepek , Julia Seyfarth , Marc Jacobsen

Tuberculosis (TB) is characterized by immunopathology in the blood and monocytes have been shown to be highly sensitive to plasma environment changes in TB patients. Here, we investigated TB plasma effects on ‘reference monocytes’ using RNA sequencing to characterize a potential immunomodulatory role of monocytes in TB. Candidate pathways induced by plasma samples from TB patients (n=99) compared to healthy controls (n=62) were analyzed for changes in signal transduction, phenotype and secreted cytokines by flow cytometry. Finally, potential implications were characterized in blood samples from corresponding patients and controls.

Reference monocytes treated with TB plasma showed an enrichment of pathways involved in inflammation and chemotaxis. Inflammatory cytokines were accompanied by enhanced phosphorylation of STAT molecules (i.e., STAT1/3/5), and strong positive correlations were detected for Interleukin (IL)-6 only in TB plasma-treated monocytes. Moreover, monocyte chemokine receptors (i.e., CCR-1, CCR-5) and pro-inflammatory chemokines (i.e., CXCL-1, CXCL-2, CXCL-8, G-CSF, CCL-2) that attract granulocytes and monocytes were significantly higher in TB plasma-treated monocytes. Notably, corresponding clinical samples also showed higher plasma levels for a subset of inflammatory cytokines/chemokines and, in particular, high IL-6 levels correlated positively with accumulation of neutrophil granulocytes in the blood of TB patients. Finally, monocytes from TB patients were characterized by increased chemokine receptor expression, higher proportions of a CCR-2⁺ subpopulation and aberrant high SOCS3 expression.

These results suggest that monocytes may play a significant role in amplifying plasma immunopathology, leading to sustained mobilization and accumulation of neutrophil granulocytes and chronic inflammation in the blood of TB patients.

结核病（TB）以血液中的免疫病理为特征，而单核细胞已被证明对结核病患者血浆环境的变化高度敏感。在此，我们利用 RNA 测序研究了结核病血浆对 "参考单核细胞 "的影响，以确定单核细胞在结核病中的潜在免疫调节作用。通过流式细胞术分析了结核病患者血浆样本（n=99）与健康对照组血浆样本（n=62）相比在信号转导、表型和分泌细胞因子方面的变化。最后，对相应患者和对照组血液样本的潜在影响进行了表征。用结核病血浆处理的参考单核细胞显示，参与炎症和趋化的途径丰富。炎症细胞因子伴随着 STAT 分子（即 STAT1/3/5）磷酸化的增强，仅在结核病血浆处理过的单核细胞中检测到与白细胞介素（IL）-6 呈强正相关。此外，在结核病血浆处理过的单核细胞中，吸引粒细胞和单核细胞的单核细胞趋化因子受体（即 CCR-1、CCR-5）和促炎趋化因子（即 CXCL-1、CXCL-2、CXCL-8、G-CSF、CCL-2）明显升高。值得注意的是，相应的临床样本也显示血浆中炎症细胞因子/趋化因子的水平较高，尤其是 IL-6 的高水平与结核病患者血液中中性粒细胞的积累呈正相关。最后，肺结核患者的单核细胞具有趋化因子受体表达增加、CCR-2+ 亚群比例较高和 SOCS3 异常高表达的特点。这些结果表明，单核细胞可能在放大血浆免疫病理方面发挥了重要作用，导致结核病患者血液中中性粒细胞的持续动员和积累以及慢性炎症。

{"title":"Monocyte transcriptome signatures of inflammation and enhanced neutrophil recruitment characterize immunopathology in the blood of tuberculosis patients","authors":"Hubert Senanu Ahor , Monika M. Vivekanandan , Ernest Adankwah , Difery Minadzi , Isaac Acheampong , Wilfred Aniagyei , Augustine Yeboah , Joseph F. Arthur , Millicent Lamptey , Mohammed K. Abass , Francis Kumbel , Francis Osei-Yeboah , Amidu Gawusu , Patrick Petzsch , Karl Köhrer , Linda Batsa Debrah , Dorcas O. Owusu , Alexander Debrah , Ertan Mayatepek , Julia Seyfarth , Marc Jacobsen","doi":"10.1016/j.jinf.2024.106359","DOIUrl":"10.1016/j.jinf.2024.106359","url":null,"abstract":"<div><div>Tuberculosis (TB) is characterized by immunopathology in the blood and monocytes have been shown to be highly sensitive to plasma environment changes in TB patients. Here, we investigated TB plasma effects on ‘reference monocytes’ using RNA sequencing to characterize a potential immunomodulatory role of monocytes in TB. Candidate pathways induced by plasma samples from TB patients (n=99) compared to healthy controls (n=62) were analyzed for changes in signal transduction, phenotype and secreted cytokines by flow cytometry. Finally, potential implications were characterized in blood samples from corresponding patients and controls.</div><div>Reference monocytes treated with TB plasma showed an enrichment of pathways involved in inflammation and chemotaxis. Inflammatory cytokines were accompanied by enhanced phosphorylation of STAT molecules (i.e., STAT1/3/5), and strong positive correlations were detected for Interleukin (IL)-6 only in TB plasma-treated monocytes. Moreover, monocyte chemokine receptors (i.e., CCR-1, CCR-5) and pro-inflammatory chemokines (i.e., CXCL-1, CXCL-2, CXCL-8, G-CSF, CCL-2) that attract granulocytes and monocytes were significantly higher in TB plasma-treated monocytes. Notably, corresponding clinical samples also showed higher plasma levels for a subset of inflammatory cytokines/chemokines and, in particular, high IL-6 levels correlated positively with accumulation of neutrophil granulocytes in the blood of TB patients. Finally, monocytes from TB patients were characterized by increased chemokine receptor expression, higher proportions of a CCR-2<sup>+</sup> subpopulation and aberrant high SOCS3 expression.</div><div>These results suggest that monocytes may play a significant role in amplifying plasma immunopathology, leading to sustained mobilization and accumulation of neutrophil granulocytes and chronic inflammation in the blood of TB patients.</div></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"89 6","pages":"Article 106359"},"PeriodicalIF":14.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reassessing feature importance biases in machine learning models for infection analysis 重新评估用于感染分析的机器学习模型中的特征重要性偏差。

IF 14.3 1区医学 Q1 INFECTIOUS DISEASES

Journal of Infection

Pub Date : 2024-11-16 DOI: 10.1016/j.jinf.2024.106357

Yoshiyasu Takefuji

引用次数: 0

On the prevalence of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome after a SARS-CoV-2 infection 关于 SARS-CoV-2 感染后肌痛性脑脊髓炎/慢性疲劳综合征的发病率。

IF 14.3 1区医学 Q1 INFECTIOUS DISEASES

Journal of Infection

Pub Date : 2024-11-16 DOI: 10.1016/j.jinf.2024.106353

Nuno Sepúlveda, Francisco Westermeier

引用次数: 0

Genomic integrity in Bordetella pertussis: avoiding contaminant-derived misinterpretations of acquired antimicrobial resistance 百日咳杆菌基因组的完整性：避免由污染物引起的对获得性抗菌药耐药性的误读。

IF 14.3 1区医学 Q1 INFECTIOUS DISEASES

Journal of Infection

Pub Date : 2024-11-16 DOI: 10.1016/j.jinf.2024.106356

Yilu Zhuang, Shuangshuang Li, Danni Bao, João Pedro Rueda Furlan, Zhi Ruan

引用次数: 0

African swine fever virus in China: The diagnostic target gene (B646L) has acquired multi-point mutations 中国非洲猪瘟病毒：诊断目标基因（B646L）发生多点突变。

IF 14.3 1区医学 Q1 INFECTIOUS DISEASES

Journal of Infection

Pub Date : 2024-11-15 DOI: 10.1016/j.jinf.2024.106351

Lei-lei Ding , Zhi-gang Wang , Tian-peng Wang, Zhen-jiang Zhang, Feng-wei Jiang, Lin-fei Song, Kun Xue, Fang Li, Ren-qiang Liu, Zhi-gao Bu, Xiao-dong Wu, En-cheng Sun, Dong-ming Zhao

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of Infection

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀